Quest PharmaTech subsidiary OncoQuest completed enrollment for a Phase I/II clinical study for the use of oregovomab with Nivolumab in ovarian cancer patients.
Quest PharmaTech (TSXV:QPT) announced its subsidiary OncoQuest completed enrollment for a Phase I/II clinical study for the use of oregovomab with Nivolumab in ovarian cancer patients.
As quoted in the press release:
This clinical trial is being conducted at the National Cancer Centre in Singapore (“NCCS”), with Dr. Tira Tan as Principal Investigator, Adjunct Associate Professor John Chia from Oncocare Cancer Centre as the Study Chair, and Dr. Jack Chan as the co-chair.
“We are extremely excited about launching this study,” noted Dr. John Chia. “Ovarian cancer is a lethal disease, and this trial may offer new hope for our patients. Early clinical data suggests that oregovomab may improve the immune system’s processing of cancer antigens, and enhance the immune ability to recognize these cancer targets. We believe that the combination of oregovomab and Nivolumab, which amplifies such immune activity, will have a synergistic effect to elicit a higher quality tumor immune response, and hence improve control of the cancer.” This will be the first clinical trial testing the combination of oregovomab with a checkpoint inhibitor as potential treatment of ovarian cancer in the recurrent setting.